New Preclinical Simulation Data Shows Superior Effect of Realheart® TAH in Regulating Cardiovascular Function During Sleep
Västerås, Sweden, November 21, 2024 – Scandinavian Real Heart AB (publ) announces today that the company presented updated safety data from a preclinical study with Realheart® TAH at the 30th Annual Meeting of ISMCS 2024. At the meeting, the company’s R&D engineer Faisal Zaman was nominated for the Helmut Reul Young Investigator Award, a prestigious award that recognizes ground-breaking innovation.
Besides presenting positive results from two preclinical studies, earlier communicated in a press release on September 5, Realheart now presented promising results concerning cardiac output during sleep and exercise.
In the current studies, the performance of Realheart® TAH was compared to a market-leading product. Simulation results show that Realheart TAH's automatically regulated cardiac output is superior to the market-leading product in adapting to patient needs, both during sleep and exercise.
“This is very promising data as it is likely that patients will have a better quality of life if the artificial heart can automatically adapt to the body's activity level. We are committed to developing an artificial heart that mimics the physiological heart as closely as possible, and the research results presented at the ISMCS meeting reveal yet another aspect in which we are successful in this ambition,” said Ina Laura Perkins, CEO of Realheart.
During ISMCS, Realheart R&D engineer Faisal Zaman was nominated for the Helmut Reul Young Investigator Award for his contributions to the research and development of Realheart® TAH. The nomination meant that the research results were presented in the opening session of the conference and thus to a packed auditorium.